IN2014CN04809A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04809A
IN2014CN04809A IN4809CHN2014A IN2014CN04809A IN 2014CN04809 A IN2014CN04809 A IN 2014CN04809A IN 4809CHN2014 A IN4809CHN2014 A IN 4809CHN2014A IN 2014CN04809 A IN2014CN04809 A IN 2014CN04809A
Authority
IN
India
Prior art keywords
tbut
prolongs
treatment
disclosed
dry eye
Prior art date
Application number
Inventor
Joseph G Vehige
Peter A Simmons
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014CN04809(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2014CN04809A publication Critical patent/IN2014CN04809A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/717Celluloses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A salt free emulsion for the treatment of dry eye and other ocular conditions is disclosed which contains castor oil and does not contain olive oil which prolongs TBUT and provides superior comfort.
IN4809CHN2014 2011-12-07 2012-12-07 IN2014CN04809A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161568089P 2011-12-07 2011-12-07
US201261625401P 2012-04-17 2012-04-17
PCT/US2012/068615 WO2013086449A1 (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Publications (1)

Publication Number Publication Date
IN2014CN04809A true IN2014CN04809A (en) 2015-09-18

Family

ID=47459152

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4809CHN2014 IN2014CN04809A (en) 2011-12-07 2012-12-07

Country Status (28)

Country Link
US (2) US9314528B2 (en)
EP (4) EP3981387A1 (en)
JP (1) JP6142419B2 (en)
KR (1) KR102017922B1 (en)
CN (2) CN104114152A (en)
AR (1) AR089123A1 (en)
AU (2) AU2012347459A1 (en)
BR (1) BR112014013820A8 (en)
CA (1) CA2858574C (en)
CL (1) CL2014001518A1 (en)
CO (1) CO6990739A2 (en)
DK (2) DK2787969T3 (en)
ES (2) ES2896336T3 (en)
HK (2) HK1201458A1 (en)
HU (2) HUE049489T2 (en)
IL (1) IL233008A (en)
IN (1) IN2014CN04809A (en)
MX (1) MX355216B (en)
MY (1) MY173378A (en)
PH (1) PH12014501296A1 (en)
PL (2) PL2787969T3 (en)
PT (2) PT2787968T (en)
RU (1) RU2014127074A (en)
SG (1) SG11201403013VA (en)
SI (2) SI2787969T1 (en)
TW (1) TWI652072B (en)
WO (2) WO2013086449A1 (en)
ZA (1) ZA201404228B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
ES2706535T3 (en) 2016-07-07 2019-03-29 Salvat Lab Sa Ophthalmic compositions comprising castor oil and medium chain triglycerides
EP3500344A4 (en) 2016-08-19 2020-08-05 Akrivista, LLC Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
CN111295169A (en) 2017-08-18 2020-06-16 阿克里维斯塔有限责任公司 Methods of diagnosing and treating dry eye syndrome and compositions for treating human eyes
US11096958B2 (en) 2018-04-27 2021-08-24 Allergan, Inc. Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
DE3066859D1 (en) * 1979-10-26 1984-04-12 Smith & Nephew Ass Autoclavable emulsions
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1224795B (en) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti USE OF ACETYL D-CARNITINE IN THE THERAPEUTIC TREATMENT OF GLAUCOMA AND PHARMACEUTICAL COMPOSITIONS USEFUL IN SUCH TREATMENT
ES2038580T3 (en) 1989-08-03 1994-10-16 Eisai Co Ltd PHOTOSTABILIZATION METHOD OF OPHTHALMIC SOLUTIONS.
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (en) 1992-09-04 1994-03-10 Basotherm Gmbh Medicines for topical use on the eye to treat increased intraocular pressure
CA2199610A1 (en) 1994-09-14 1996-03-21 Taisho Pharmaceutical Co., Ltd. Eye drops for repairing repairing corneal damage
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (en) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Use of trimethylglycine in preparations for hygiene and care of the mucous membranes of the body
AR002194A1 (en) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany COMPUTERIZED INSTRUMENT FOR THE ANALYSIS OF MOVEMENT.
IT1302307B1 (en) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa COMPOSITION WITH ANTIOXIDANT ACTIVITY AND FOR IMPROVING THE METABOLIC USE OF GLUCOSE, INCLUDING ACETYL
ES2228128T3 (en) 1998-11-13 2005-04-01 Continental Projects Limited HIALURONIC ACID COMPLEX / CARNITINE AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS.
JP2000159659A (en) * 1998-11-30 2000-06-13 Kazuo Tsubota Artificial lachrymal fluid for ophthalmology
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
RU2291685C2 (en) 2000-07-14 2007-01-20 Аллерган Инк. Composition containing therapeutically active ingredients having increased solubility
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
AU2720602A (en) 2000-11-08 2002-05-21 Bio Concept Lab Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
WO2004028536A1 (en) 2002-09-30 2004-04-08 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
WO2004035005A2 (en) * 2002-10-18 2004-04-29 Echols Joel S Three layer tear formulation
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
WO2004084877A1 (en) 2003-03-26 2004-10-07 Menicon Co., Ltd. Composition for ophthalmic use
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
JP4860475B2 (en) * 2003-06-13 2012-01-25 アルコン,インコーポレイテッド Ophthalmic composition comprising a synergistic combination of two polymers
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
CA2549737A1 (en) * 2003-11-10 2005-05-26 Toray Industries, Inc. Polysaccharide-containing composition and tear film stabilizing ophthalmic solution
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101896160A (en) * 2006-10-17 2010-11-24 阿勒根公司 Cyclosporin compositions
CA2679448A1 (en) 2007-02-28 2008-09-04 Aciex, Inc. Methods and compositions for normalizing meibomian gland secretions
JP4929245B2 (en) 2008-07-31 2012-05-09 株式会社ベッセル工業 Tool grip
WO2010141648A2 (en) * 2009-06-05 2010-12-09 Allergan, Inc. Artificial tears and therapeutic uses
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye

Also Published As

Publication number Publication date
PT2787968T (en) 2020-06-16
WO2013086438A1 (en) 2013-06-13
EP2787969A1 (en) 2014-10-15
EP3666257A1 (en) 2020-06-17
CA2858574A1 (en) 2013-06-13
AU2017265181A1 (en) 2017-12-14
KR102017922B1 (en) 2019-09-03
DK2787968T3 (en) 2020-06-02
WO2013086449A1 (en) 2013-06-13
KR20140107383A (en) 2014-09-04
HK1203057A1 (en) 2015-10-16
AR089123A1 (en) 2014-07-30
CL2014001518A1 (en) 2014-10-24
MX355216B (en) 2018-04-10
EP2787968A1 (en) 2014-10-15
RU2014127074A (en) 2016-02-10
RU2018119362A3 (en) 2021-09-07
TWI652072B (en) 2019-03-01
CA2858574C (en) 2017-05-30
HUE057140T2 (en) 2022-04-28
RU2018119362A (en) 2018-11-08
PL2787969T3 (en) 2021-12-20
IL233008A0 (en) 2014-07-31
BR112014013820A2 (en) 2017-06-13
HUE049489T2 (en) 2020-09-28
CN108969482A (en) 2018-12-11
CO6990739A2 (en) 2014-07-10
BR112014013820A8 (en) 2017-06-13
JP2015504860A (en) 2015-02-16
PL2787968T3 (en) 2020-08-24
PH12014501296A1 (en) 2014-10-08
HK1201458A1 (en) 2015-09-04
US9314528B2 (en) 2016-04-19
ZA201404228B (en) 2015-12-23
IL233008A (en) 2017-07-31
ES2896336T3 (en) 2022-02-24
AU2017265181B2 (en) 2019-06-20
SI2787968T1 (en) 2020-08-31
EP2787968B1 (en) 2020-03-04
DK2787969T3 (en) 2021-11-01
MY173378A (en) 2020-01-21
PT2787969T (en) 2021-11-09
CN104114152A (en) 2014-10-22
MX2014006804A (en) 2014-09-22
US20130150324A1 (en) 2013-06-13
SG11201403013VA (en) 2014-07-30
AU2012347459A1 (en) 2014-07-03
US20130197083A1 (en) 2013-08-01
TW201325633A (en) 2013-07-01
EP3981387A1 (en) 2022-04-13
EP2787969B1 (en) 2021-09-29
ES2797650T3 (en) 2020-12-03
JP6142419B2 (en) 2017-06-07
SI2787969T1 (en) 2021-12-31

Similar Documents

Publication Publication Date Title
MY171920A (en) Prevention and treatment of ocular conditions
HK1222116A1 (en) Drain valve implantable in the eye of a patient for the treatment of glaucoma
HRP20130830T1 (en) A water-in-oil type emulsion for treating a disease of the eye
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
MX362185B (en) Compositions and treatment for eye diseases and disorders.
IN2014CN04809A (en)
HK1201438A1 (en) Treatment of ocular disease
IN2014CN03123A (en)
MX2014000781A (en) Fixed dose combination of bimatoprost and brimonidine.
HK1186660A1 (en) A water-in-oil type emulsion for treating a disease of the eye
EP3013425A4 (en) Treatment and diagnosis of ocular disease
UY34843A (en) TREATMENT OF OCULAR INFLAMMATORY DISEASES USING LAQUINIMOD
EP3182952A4 (en) Modifying humidity to glabrous tissue for the treatment of migraine and other conditions
EP3145532A4 (en) Individualized treatment of eye disease
HK1220144A1 (en) Use of n-(4-tert-butylbenzyl)-3-chloro-n-[2-(4-chloro-3-ethyl- phenyl)-ethyl]-2-fluoro- 5-trifluoromethyl-benzamide for the treatment of eye diseases n-(4--)-3--n-[2-(4--3--)-]-2--5--
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
MX2016005505A (en) Cetp modulator for use in the treatment of eye disease.
HK1216233A1 (en) Agent for preventing or treating diseases of posterior part of the eye and containing tetrahydropyranyl amino cyclopentylcarbonyl tetrahydropyridopyridine derivative as active component
UA113065C2 (en) SKIN COMPOSITION AND APPLICATION
UA111645C2 (en) EFFICIENT DELIVERY OF LIPIDES INTO THE TREATMENT OF HUMAN FILM USING THE SALT-EMULSIVE SYSTEM
PL401911A1 (en) Use of the preparation with the immunoregulatory properties
CN302327175S (en) glasses
MX2013006527A (en) Arylsulfonamide derivatives for the prevention or treatment of specific ophthalmologic disorders.